|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 165.00 USD | -5.17% |
|
-26.35% | -58.51% |
| 10-30 | BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says | MT |
| 10-30 | Alnylam Faces Near-Term Risk on Amvuttra, Oppenheimer Says | MT |
| Market Cap | 22.1B 19.79B 18.21B 16.5B 30.84B 2,098B 31.41B 217B 87.15B 1,104B 82.94B 81.17B 3,481B | P/E 2026 * |
9.41x | P/E 2027 * | 17.9x |
|---|---|---|---|---|---|
| Enterprise Value | 19.61B 17.56B 16.15B 14.64B 27.36B 1,862B 27.87B 193B 77.33B 979B 73.59B 72.03B 3,089B | EV / Sales 2026 * |
3.6x | EV / Sales 2027 * | 2.68x |
| Free-Float |
99.77% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALNY | Delayed | |
CBOE
| ALNY | Real-time | |
|
Tradegate
| DUL | Real-time | |
|
Boerse Muenchen
| DUL | Real-time | |
|
London S.E.
| 0HD2 | Delayed | |
|
Xetra
| DUL | End-of-day quote | |
|
Berne S.E.
| DUL | End-of-day quote | |
|
Börse Stuttgart
| DUL | Delayed | |
|
Deutsche Boerse AG
| DUL | Delayed | |
|
Borsa Italiana
| 1ALNY | End-of-day quote | |
|
Wiener Boerse
| ALNY | End-of-day quote |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | -5.17% | ||
| 1 week | -26.35% | ||
| 1 month | -33.13% | ||
| 3 months | -19.72% | ||
| 6 months | -46.69% | ||
| Current year | -58.51% |
| 1 week | 163.3 |  | 232.88 |
| 1 month | 163.3 | | 238.96 |
| Current year | 163.3 | | 427.05 |
| 1 year | 163.3 | | 479.79 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/01/2022 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 13/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 01/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 23/04/2012 |
Amy Schulman
CHM | Chairman | 65 | 05/01/2023 |
David Pyott
BRD | Director/Board Member | 72 | 18/12/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/2/26 A | Sell | General Counsel | -1,758 | 0.0013% | ||
| 9/19/26 A | Free | Chief Executive Officer | 107 | 0.0001% | ||
| 6/1/26 A | Exercice | Director | 11,490 | 0.0086% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.17% | -26.35% | -63.82% | +8.70% | 22.1B | |
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | |
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | |
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | |
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | |
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | |
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | |
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | |
| Average | +1.36% | +2.67% | +35.54% | +76.97% | 428.4B | |
| Weighted average by Cap. | +1.97% | +6.43% | +49.92% | +99.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.44B 4.87B 4.48B 4.06B 7.59B 517B 7.74B 53.47B 21.47B 272B 20.43B 19.99B 857B | 6.63B 5.93B 5.46B 4.95B 9.24B 629B 9.42B 65.09B 26.13B 331B 24.87B 24.34B 1,044B |
| Net income | 2.39B 2.14B 1.97B 1.78B 3.33B 227B 3.39B 23.46B 9.42B 119B 8.96B 8.77B 376B | 1.17B 1.04B 960M 870M 1.63B 111B 1.66B 11.45B 4.59B 58.19B 4.37B 4.28B 184B |
| Net Debt | -2.49B -2.23B -2.05B -1.86B -3.48B -236B -3.54B -24.47B -9.82B -124B -9.35B -9.15B -392B | -4.34B -3.89B -3.57B -3.24B -6.05B -412B -6.17B -42.63B -17.11B -217B -16.29B -15.94B -684B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | $165.00 | -5.17% | 7,056,827 |
| 29/10/26 | $174.00 | -25.13% | 11,802,855 |
| 28/10/26 | $232.40 | +2.47% | 1,944,031 |
| 27/10/26 | $226.79 | -0.38% | 1,603,484 |
| 26/10/26 | $227.66 | +1.62% | 1,436,998 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
